Read this company snapshot
Daily valuation snapshot
Belite Bio, Inc American Depositary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $154.49
- Market capitalization (USD)
- $6,077,630,420.4
- Price / earnings (TTM)
- Not reported
- Price / book
- 7.89
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research BLTE in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research BLTE in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing BLTE with another company.
| Daily close (USD) | $154.49 |
| Market capitalization (USD) | $6,077,630,420.4 |
| Price / earnings (TTM) | Not reported |
| Price / book | 7.89 |
No matching rows. Clear the filter to see all records.
Read BLTE's valuation metrics
Company size
Belite Bio, Inc American Depositary Shares's recorded market capitalization is $6,077,630,420.4. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
BLTE's recorded price-to-book ratio is 7.89. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Belite Bio, Inc American Depositary Shares with Aurora
Use the snapshot above to ask a specific question about BLTE. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow BLTE's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.